MTOR and neoplasm: MiR-100 reduces the protein level of angiopoietin 2 (Angpt2) by targeting mTOR and blocking the mTOR-p70S6K signaling pathway, which in turn inhibits the formation of encapsulated tumor clusters (VETC), thereby eliminating VETC-dependent metastasis of HCC cells.